[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.106.142. Please contact the publisher to request reinstatement.
Dermatology

Five-Year Survival Among Patients With Advanced Skin, Renal, and Lung Cancer Treated With Nivolumab

JAMA Oncology
July 25, 2019 Audio Author Interview 19 min 25 sec
<title>Five-Year Survival Among Patients With Advanced Skin, Renal, and Lung Cancer Treated With Nivolumab</title>
Download MP3

Interview with Suzanne L. Topalian, MD, author of Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
Subscribe

Subscribe on your favorite podcast source to receive future episodes of this podcast.
Learn more about this JAMA Network podcast here

Related Articles

  1. Five-Year Survival Among Patients With Advanced Skin, Renal, and Lung Cancer Treated With Nivolumab
    1.00 CME

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

See More About

Dermatology Lung Cancer Melanoma Nephrology Targeted and Immune Cancer Therapy Oncology Skin Cancer Urology Urologic Cancer
Close

Name Your Search

Save Search
Privacy Policy|Terms of Use
Close
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
Close
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue